NF-κB

Bortezomib-d8 (PS-341-d8) is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity.

Demethyleneberberine chloride is a natural mitochondrial-targeted antioxidant. It alleviates colitis in mice and inhibits inflammatory responses by suppressing the NF-κB pathway and regulating Th cell balance. Demethyleneberberine chloride can also serve as an AMPK activator for research on non-alcoholic fatty liver disease (NAFLD).

HE 3286 is a synthetic derivative of the natural anti-inflammatory steroid β-AET. HE 3286 is an orally active partial inhibitor of NF-κB. It reduces pro-inflammatory signals, including IL-6 and matrix metalloproteinase 3. HE 3286 can freely cross the blood-brain barrier in mice. HE 3286 can be used for research on ulcerative colitis, arthritis, and experimental autoimmune encephalomyelitis.

Nasunin is an antioxidant anthocyanin with anti-angiogenic activity.

NF-κB-IN-4 (compound 17) is an effective NF-κB pathway inhibitor that can penetrate the blood-brain barrier. NF-κB-IN-4 exhibits potential low toxicity and anti-neuroinflammatory activity. It can block the activation and phosphorylation of IκBα, reduce the expression of NLRP3, and thus inhibit the activation of NF-κB. NF-κB-IN-4 can be used for research on neuroinflammatory-related diseases.

NF-κB/MAPK-IN-1 (compound 11a) is an effective inhibitor of the NF-κB and MAPK pathways. It has inhibitory effects on NO production, with an IC50 of 6.96 μM. NF-κB/MAPK-IN-1 also inhibits LPS-induced iNOS, COX-2, ERα, and P38 activation. It can inhibit macrophage inflammatory response induced by LPS. NF-κB/MAPK-IN-1 can be used for research on rheumatoid arthritis (RA).

(R)-(-)-Ibuprofen-d3 is the deuterated form of (R)-(-)-Ibuprofen. (R)-(-)-Ibuprofen is the R enantiomer of Ibuprofen, which has no effect on COX and can inhibit NF-κB activation. (R)-(-)-Ibuprofen has anti-inflammatory properties and can be used in pain relief research.

3'-Sialyllactose (3'-SL) is a prebiotic, maintains immune homeostasis and exerts anti-inflammatory and anti-arthritic effects.

S-HP210 is a potent and selective glucocorticoid receptor (GR) with an IC50 value of 1.92 μM for NF-κB transrepression (TR).

R-HP210 acts on the NF-κB mediated tethered transrepression function (IC50=3.80μM).

ALPK1-IN-1 (Compound A001) is a potent inhibitor of alpha-kinase 1 (ALPK1).

Anti-inflammatory agent 51 (compound 11d) is an amide/sulfonamide derivative with anti-inflammatory activities.

ALPK1-IN-3 is an inhibitor of ALPK1 extracted from patent WO2022063153A1 compound T007.

7-O-Methylaloesinol is a chromone derivative.

Alphitolic acid, a pentacyclic triterpenoid with a lupane skeleton, exhibits anti-inflammatory and cytotoxic activities.

Pratol is a potent inhibitor of NF-κB.

Tripeptide-41(CG-Lipoxyn)isa bioactive peptide withreduce fat accumulationeffect and has been reported used as a cosmetic ingredient.

SPC 839 (compound 10) is an orally active inhibitor of AP-1 and NF-kB mediated transcriptional activation with IC50 of 0.008 μM.

Helenalin acetate, a natural NF-κB inhibitor, is a potent C/EBPβ inhibitor.

CPS-11 (N-(droxymetl)thalidomide) a Thalidomide analogue, is a potent anti-cancer agent.

K284-6111 is an orally active inhibitor for protein chitinase 3-like 1 (CHI3L1).